Özet:

Target: Thyroid hormone receptor Interactive Protein 13 (TRIP13) is a protein that plays a role in mayotic recombination, which is responsible for the network-accumulation control point. Recent studies have shown that TRIP13 may be a potential tumor in many cancers, including glioblastoma multiforme (GBM). This study was aimed at investigating the anti-cancer effectiveness of the U87 human GBM cells of DCZ0415, a small molecular inhibitor of TRIP13. The potential anti-cancer effect of DCZ0415 in the U87 cells was determined by cytotoxicity analysis, colony formation analysis and apoptosis analysis. The QRT-PZR analysis also studied the effect of DCZ0415 on the mRNA levels of genes associated with apoptosis, invasion and transformer growth factor-beta (TGF-β) signal pathway. Results: DCZ0415, inhibited the proliferation of the U87 cell depending on dose and time. In the U87 cells, the IC50 dose for 48 hours of DCZ0415 was determined at 19.77 μM. In this dose, the application DCZ0415 induced apoptosis in the U87 cells and suppressed the capabilities of the cells to create colonies. DCZ0415 also changed the mRNA levels of the apoptosis, invasion and TGF-β signal path related genes in such a way that they could lead to anti-cancer effects. The result: DCZ0415, an inhibitor of TRIP13, which is considered a new oncogenic factor in cancer, has an anti-cancer effect in GBM cells. In this regard, it is believed that TRIP13 could be a major therapeutic target for GBM and that DCZ0415 could be considered an effective inhibitor that leads to an anti-cancer effect in GBM cells.